Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan

Reuptake Inhibition

  • Chava CrequeEmail author
  • Stephanie A. Kolakowsky-Hayner
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_1750


Impaired reabsorption


Reuptake inhibition is used to increase the amount of neurotransmitter present within the synapse. This subsequently increases the availability of that neurotransmitter to bind to the postsynaptic receptor. Reuptake inhibition effectively prevents the reabsorption of the secreted substance (typically a neurotransmitter) back into the presynaptic cell. Drugs that use reuptake inhibition as their mechanism of action include Zoloft, Paxil, and Prozac. Reuptake inhibitors are used to treat clinical depression, several anxiety disorders, and post-traumatic stress disorder. Recent studies have also yielded promising findings in the use of certain reuptake inhibitors to treat some symptoms of disorders like schizophrenia and Parkinson’s disease. Commonly used reuptake inhibitors are the selective serotonin reuptake inhibitors (SSRIs), which act to increase the availability of serotonin by inhibiting reabsorption of serotonin, therefore increasing the...

This is a preview of subscription content, log in to check access.

References and Readings

  1. Baldwin, D. (2006). Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders. International Journal of Psychiatry in Clinical Practice, 10, 12–15.PubMedCrossRefGoogle Scholar
  2. Delgado, P. (2006). Serotonin noradrenaline reuptake inhibitors: New hope for the treatment of chronic pain. International Journal of Psychiatry in Clinical Practice, 10, 16–21.PubMedCrossRefGoogle Scholar
  3. Jordan, A., Jackson, G., Deardorff, D., Shivakumar, G., McIntire, D., & Dashe, J. (2008). Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. Journal of Maternal-Fetal & Neo-natal Medicine, 21(10), 745–751.CrossRefGoogle Scholar
  4. Montgomery, S. (2006). Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development. International Journal of Psychiatry in Clinical Practice, 10, 5–11.PubMedCrossRefGoogle Scholar
  5. Rivas-Vazquez, R., Johnson, S., Blais, M., & Rey, G. (1999). Selective serotonin reuptake inhibitor discontinuation syndrome: Understanding, recognition, and management for psychologists. Professional Psychology: Research and Practice, 30(5), 464–469.CrossRefGoogle Scholar
  6. Umbricht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E., Ostland, M., Wallace, T. L., Knoflach, F., Dorflinger, E., Wettstein, J. G., Bausch, A., Garibaldi, G., & Santarelli, L. (2014). Effect of bitopertin, a glyce reuptake inhibitor, on negative symptoms of schizophrenia: A random, double-blind, proof-of concept study. JAMA Psychiatry, 71(6), 637–646.PubMedCrossRefGoogle Scholar
  7. Ye, Z., Altena, E., Nombela, C., Housden, C. R., Maxwell, H., Rittman, T., Huddleston, C., Rae, C. L., Regenthal, R., Sahakian, B. J., Barker, R. A., Robbins, T. W., & Rowe, J. B. (2014). Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease. Brain, 2014, awu032.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychology and NeuroscienceUniversity of Colorado BoulderBoulderUSA
  2. 2.Department of Rehabilitation Medicine, Icahn School of Medicine at Mount SinaiNew YorkUSA